The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked Off
The largest Phase 3 clinical trial investigating the efficacy and tolerability of psilocybin for treatment-resistant depression (TRD) has finally begun.
treatment-resistant depression
-
-
COVID-19 Pandemic Study of Ketamine Therapy Amplifies Antidepressant Potential
Study authors even believe “treating serious mental illness may reduce adverse outcomes related to COVID-19.”
-
Big Pharma Giant Merck Partners With Psychedelic Research Company Novamind
Pharmaceutical giant Merck is partnering with psychedelic research company Novamind to test a possible therapy for treatment-resistant depression.
